OPA1

Dynamin-like GTPase OPA1, mitochondrial · O60313 · OPA1 on Sugi Atlas →

1,823 patent compounds predicted against OPA1, 1,503 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tivantinib (SCHEMBL44902)	1.00	1/20
Tivantinib (SCHEMBL44944)	1.00	1/20
Tivantinib (SCHEMBL45306)	1.00	1/20
Tivantinib (SCHEMBL224883)	1.00	1/20
Tivantinib (SCHEMBL1395795)	1.00	1/20
Tivantinib (SCHEMBL2036414)	1.00	1/20
Momelotinib (SCHEMBL2237234)	1.00	1/20
Momelotinib (SCHEMBL2863013)	0.98	1/20
Momelotinib (SCHEMBL2863022)	0.98	1/20
Momelotinib (SCHEMBL3619656)	0.93	1/20
Momelotinib (SCHEMBL3619662)	0.93	1/20
Tivantinib (SCHEMBL2015821)	0.92	1/20
SCHEMBL2858799	0.89	1/20
SCHEMBL2344229	0.88	1/20
SCHEMBL3689556	0.88	1/20
SCHEMBL3689562	0.88	1/20
SCHEMBL2879596	0.87	1/20
SCHEMBL2879812	0.87	1/20
SCHEMBL3114656	0.87	1/20
SCHEMBL3120542	0.87	1/20

Clinical trials — most relevant to OPA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease	PHASE3	RECRUITING
Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy	PHASE3	COMPLETED
Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial	PHASE3	RECRUITING
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)	PHASE1/PHASE2	RECRUITING
The KHENEREXT Study	PHASE2	COMPLETED
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)	PHASE1	ACTIVE_NOT_RECRUITING
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)	PHASE1	RECRUITING
Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	PHASE1	COMPLETED
Trial of Oxaloacetate in ALS	PHASE1	COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	EARLY_PHASE1	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure?	nan	RECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
The Natural History of Mitochondrial Diseases	nan	RECRUITING
Paediatric Obesity and Cardiovascular Dysfunction	nan	COMPLETED
MITAORTA - Role of Mitochondrial Dynamic in Aneurysm and Dissection of Ascending Thoracic Aorta	nan	ACTIVE_NOT_RECRUITING
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Diagnostic Odyssey Survey 2	nan	COMPLETED
Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults	nan	COMPLETED
Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy	nan	RECRUITING
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders	nan	COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Mitochondrial Video Assessment Source Material Study	nan	COMPLETED
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients	nan	UNKNOWN
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a OPA1 binder may also engage these)

Protein	Name	Similarity
Q5F499	—	1.000	Q5F499 →
O93248	—	0.999	O93248 →
Q2TA68	—	0.999	Q2TA68 →
P58281	—	0.999	P58281 →
Q5U3A7	—	0.998	Q5U3A7 →
Q5RAM3	—	0.997	Q5RAM3 →
Q0JLS6	—	0.991	Q0JLS6 →
Q8R4Z9	—	0.990	Q8R4Z9 →
Q811U4	—	0.989	Q811U4 →
B6K0N7	—	0.989	B6K0N7 →
P32266	—	0.989	P32266 →
Q84N64	—	0.988	Q84N64 →
A6S544	—	0.988	A6S544 →
Q8IWA4	—	0.988	Q8IWA4 →
A6ZP10	—	0.987	A6ZP10 →
C5DTA7	—	0.987	C5DTA7 →
A7AT07	—	0.987	A7AT07 →
B2B1M4	—	0.987	B2B1M4 →
Q525S7	—	0.987	Q525S7 →
Q4N280	—	0.987	Q4N280 →
O18412	—	0.987	O18412 →
Q99287	—	0.986	Q99287 →
B5VS52	—	0.986	B5VS52 →
G0SGC7	—	0.986	G0SGC7 →
B3LJJ8	—	0.986	B3LJJ8 →
P93042	—	0.986	P93042 →
A2CI35	—	0.986	A2CI35 →
Q6XUX1	—	0.986	Q6XUX1 →
P87320	—	0.986	P87320 →
Q95JR3	—	0.985	Q95JR3 →